What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
Petr Widimsky mainly investigates Internal medicine, Cardiology, Myocardial infarction, Randomized controlled trial and Percutaneous coronary intervention.
His Cardiology research is multidisciplinary, incorporating elements of Fibrinolytic agent and Intensive care medicine.
The Myocardial infarction study combines topics in areas such as Stroke and Coronary artery disease.
His research on Randomized controlled trial concerns the broader Surgery.
The study incorporates disciplines such as Revascularization and Confidence interval in addition to Surgery.
In Percutaneous coronary intervention, Petr Widimsky works on issues like Thrombolysis, which are connected to Reperfusion therapy, ST elevation, Thrombus and Venous thrombosis.
His most cited work include:
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) (2467 citations)
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment eleva... (2231 citations)
- Universal definition of myocardial infarction. (2105 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and Surgery.
In the subject of general Internal medicine, his work in Conventional PCI, Clopidogrel, Acute coronary syndrome and Stroke is often linked to In patient, thereby combining diverse domains of study.
His Cardiology study frequently links to related topics such as Randomized controlled trial.
His Myocardial infarction research incorporates elements of Stent and Hazard ratio.
Petr Widimsky studied Percutaneous coronary intervention and Cardiogenic shock that intersect with Heart failure.
His work in Surgery is not limited to one particular discipline; it also encompasses Emergency medicine.
He most often published in these fields:
- Internal medicine (70.27%)
- Cardiology (59.16%)
- Myocardial infarction (38.14%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (70.27%)
- Cardiology (59.16%)
- Stroke (15.62%)
In recent papers he was focusing on the following fields of study:
Petr Widimsky focuses on Internal medicine, Cardiology, Stroke, Myocardial infarction and In patient.
Aspirin, Antithrombotic, Atrial fibrillation, Ejection fraction and Acute coronary syndrome are the primary areas of interest in his Internal medicine study.
His work on Coronary artery disease, Percutaneous coronary intervention, Conventional PCI and Cardiogenic shock is typically connected to Bundle as part of general Cardiology study, connecting several disciplines of science.
Petr Widimsky combines subjects such as Cardiac surgery and Disease with his study of Coronary artery disease.
His Percutaneous coronary intervention research includes elements of Symptom onset and Balloon.
His Stroke study incorporates themes from Stenosis, Artery, Position paper and Left atrial.
Between 2017 and 2021, his most popular works were:
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin (113 citations)
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. (46 citations)
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial (38 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
His primary areas of investigation include Internal medicine, Cardiology, Aspirin, Stroke and Rivaroxaban.
Petr Widimsky integrates several fields in his works, including Internal medicine and In patient.
His work in Myocardial infarction, Coronary artery disease, Atrial fibrillation, QRS complex and Bundle branch block are all subfields of Cardiology research.
His research in Aspirin tackles topics such as Antithrombotic which are related to areas like Cancer, Diabetes mellitus, Blood pressure, Fibrinolytic agent and Disease.
His Stroke research integrates issues from Cardiovascular care and Apixaban.
His work focuses on many connections between Rivaroxaban and other disciplines, such as Hazard ratio, that overlap with his field of interest in Absolute risk reduction, Framingham Risk Score and Vascular disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
